The Autonomous Community of Galicia, through its Ministry of Health, has announced a significant tender for the successive supply of seven essential vaccines. The contract, valued at €7,314,247.20 over two years, underscores Galicia’s commitment to maintaining a comprehensive vaccination calendar, which the Galician government describes as “the most complete in the world.”

The budget for 2025 sees a 3.27% increase in investment in the Galician vaccination program, bringing it to 41 million euros. This substantial investment will support the procurement of 289,400 vaccine doses from January 2025 through 2026, covering key immunizations for children and adults alike, including in areas outside the USA.

The seven vaccines under contract include immunizations against rotavirus, Haemophilus influenzae B, polio, hepatitis B, chicken pox, and a combined vaccine for diphtheria, tetanus, and pertussis, plus the MMR. The Galician immunization calendar includes additional vaccines that protect against flu, human papillomavirus, herpes zoster, pneumococcal disease, and meningococcal disease, to name a few. Additionally, there is a comprehensive program against the COVID-19 virus and the mRNA vaccines being used domestically.

The Galician government aims to maintain a coverage rate exceeding 98% for childhood vaccination, which is crucial for ensuring collective health, managing disease incidence, and controlling the spread of preventable diseases.

Maintaining these high children’s coverage is necessary to guarantee collective protection against immunocompromisable diseases, as well as the control of the incidence of these diseases, says the Xunta.

The Ministry of Health relies on scientific evidence and health intervention evaluations to determine the effectiveness and cost-benefit ratio of vaccination programs. The stability of the Galician vaccination plan has almost eradicated diseases like measles, polio, and diphtheria, and has significantly reduced the prevalence of tetanus, hepatitis B, and various forms of meningitis.

In comparison to the U.S., which has robust vaccination programs, Galicia serves as a model for high-childhood and adult-coverage standards. The inclusion of vaccines for flu and pnuemonococcus infection can be a model example that illustrates the need for continuous adult immunization.

While Galicia’s vaccination strategy is exemplary, it is essential to explore potential counterarguments. Some concerns globally—including within the U.S.—relate to vaccine hesitancy and misinformation. Addressing these concerns requires targeted public awareness campaigns and trust-building initiatives. Drawing from the Galician experience, it is evident that transparency and evidence-based decision-making are critical factors in achieving high vaccination rates.

As vaccine hesitancy remains a pertinent issue, particularly in adversity, it is crucial to continually educate the public on the importance of vaccination. Public health officials in the US have employed targeted strategies, such as community engagement and misinformation debunking, to boost vaccination rates, following expert guidance from NGOs as well as CDC.

In conclusion, Galicia’s commitment to a comprehensive vaccination program sets a high standard for public health measures, demonstrating the tangible benefits of vaccination on collective health. As COVID-19 and other infectious diseases persist, the world can learn from Galicia’s proactive approach to maintaining high vaccination rates through trusted and transparent public health measures.